Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBITDA (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EBITDA for 4 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 90.02% to -$5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$160.0 million through Dec 2025, up 42.34% year-over-year, with the annual reading at -$160.0 million for FY2025, 42.34% up from the prior year.
  • EBITDA for Q4 2025 was -$5.9 million at Phathom Pharmaceuticals, up from -$15.3 million in the prior quarter.
  • The five-year high for EBITDA was -$5.9 million in Q4 2025, with the low at -$78.9 million in Q1 2025.
  • Average EBITDA over 4 years is -$48.6 million, with a median of -$46.0 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 143.84% in 2024, then soared 90.02% in 2025.
  • Over 4 years, EBITDA stood at -$46.6 million in 2022, then plummeted by 49.81% to -$69.9 million in 2023, then grew by 14.97% to -$59.4 million in 2024, then skyrocketed by 90.02% to -$5.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$5.9 million, -$15.3 million, and -$59.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.